Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Events & presentations
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
07 Jul 2021
French Retail Investors Webcast on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®
29 Jun 2021 - 01 Jul 2021
Biotech Outsourcing Strategies (BOS) 2021, Virtual
24 Jun 2021 - 25 Jun 2021
UMDF Mitochondrial Medicine 2021 – virtual
15 Jun 2021
Clinical Operations Strategy Meeting online 2021
14 Jun 2021 - 18 Jun 2021
BIO US 2021 – Digital
04 Jun 2021
KOL Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment
19 May 2021 - 21 May 2021
Advanced Therapies – Virtual
01 May 2021 - 07 May 2021
2021 ARVO Annual Meeting, virtual
29 Apr 2021
Annual General Meeting 2021
27 Apr 2021 - 29 Apr 2021
Mitochondria-Targeted Drug Development Summit, Digital
View previous 9 articles
1
2
3
4
5
6
7
8
…
17
View next 9 articles
Go back to the page of the page
